MMP2 and prostate carcinoma: Matrix metalloproteinases (MMPs) are involved in tumor progression, and treatment with 10.9–87.3 μM EGCG inhibited fibroblast conditioned medium (FCM)-induced phosphorylation of ERK1/2 and/or p38 concomitant reduction in MMP-2 and -9 in human prostate carcinoma DU-145 cells.